Relationship of Glycemia to Cardiovascular Disease ... - Lipids Online

PERISCOPE: Intravascular
Ultrasound: Secondary Endpoints
0.015
Atheroma
Thickness (mm)
0.0
Atheroma
Volume (mm 3 )
0.0
Most-Diseased
10 mm (mm 3 )
0.010
0.011
-1.0
-1.5
0.005
P = 0.006
-2.0
-1.0
P = 0.06 P = 0.93
0.000
-3.0
-0.005
-4.0
-2.0
-2.1
-2.0
-0.010
-0.011
-5.0
-5.5
-0.015
-6.0
Glimepiride
-3.0
Pioglitazone
Nissen SE, et al. JAMA. 2008;299:1561–1573.
Slide Source
Lipids Online Slide Library
www.lipidsonline.org
PERISCOPE: Intravascular Ultrasound: Secondary Endpoints
Furthermore, atheroma thickness, atheroma volume, and the severity of the most diseased
10-mm segment – in addition to percent atheroma volume – were examined in the
PERISCOPE trial. All of these secondary endpoints showed trends toward benefit in the
group treated with pioglitazone.
PERISCOPE = Pioglitazone Effect on Regression of Intravascular Sonographic Coronary
Obstruction Prospective Evaluation
Reference:
Nissen SE, Nicholls SJ, Wolski K, et al, for the PERISCOPE Investigators. Comparison
of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with
type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-
1573.
Source: Lipids Online Slide Library (www.lipidsonline.org) Page 27 of 36
© 2009 Baylor College of Medicine, Houston, Texas